CA Patent

CA1338379C — Derivatives of pyrazolo[3,4-d] pyrimidine

Assigned to Nanogen Inc · Expires 1996-06-11 · 30y expired

What this patent protects

This invention is directed to novel 3,4-disubsti-tuted and 3,4,6-trisubstituted pyrazolo[3,4-d]pyrimidines and to the use of these compounds in the preparation of oligonucleotides. The invention is also directed to nucleosides and mono- and oligonucleotides comprising at least o…

USPTO Abstract

This invention is directed to novel 3,4-disubsti-tuted and 3,4,6-trisubstituted pyrazolo[3,4-d]pyrimidines and to the use of these compounds in the preparation of oligonucleotides. The invention is also directed to nucleosides and mono- and oligonucleotides comprising at least one of these pyrazolopyrimidines, and to the use of the resulting novel oligonucleotides for diagnostic purposes. The pyrazolopyrimidines of the present invention are of the formula (I): (I) The substituents are defined in the disclosure. The novel oligo- and polynucleotides are useful in the identification, isolation, localization and/or detection of complementary nucleic acid sequences of interest in cell-free or cellular systems. The invention further provides a method for identifying target nucleic acid sequences that comprises utilizing an oligo- or polynucleotide probe comprising at least one labeled pyrazolo[3,4-d]pyrimidine of the present invention.

Drugs covered by this patent

Patent Metadata

Patent number
CA1338379C
Jurisdiction
CA
Classification
Expires
1996-06-11
Drug substance claim
No
Drug product claim
No
Assignee
Nanogen Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.